Company Overview and News
Estimates for The Travelers Companies, Inc. (TRV - Free Report) have been revised upward over the past 30 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 earnings move north by a penny to $10.47. Travelers provides a wide variety of property and casualty insurance and surety products and services to businesses, organizations and individuals in the United States and select international markets.
AFG AFW TRV NTRS GTT NTRSP AFGE PGR FAF AFA AFGH
FirstEnergy Corp’s (FE - Free Report) subsidiary — Jersey Central Power & Light (JCP&L) — has sought approval from the New Jersey Board of Public Utilities (BPU) for a four-year infrastructure plan, Reliability Plus. To improve the reliability and service quality for its 1.1 million electric customers in New Jersey, the company will spend $400 million, which is more than planned annual investments.
NI DUKH YUM NTRS GTT NTRSP DUK BKHU FE BKH
Union Pacific Corporation (UNP - Free Report) is slated to release second-quarter 2018 results on Jul 19, before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 1.8%. The company posted better-than-expected earnings and revenues in the quarter. Moreover, both metrics improved on a year-over-year basis. Higher freight revenues boosted results. The company also boasts an impressive earnings history, having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 1.
UPS UNP NTRS GTT NTRSP CSX
Verizon Communications Inc. (VZ - Free Report) continues to deploy the latest 4G LTE Advanced technologies to deliver faster peak data speeds and capacity for customers, driven by customer-focused planning, disciplined engineering and constant strategic investment. With this, the telco’s customers, spread across more than 2,000 markets, can experience the benefits of carrier aggregation while those in 1,100 markets can access 4x4 MIMO (Massive Input, Massive Output) and 256 QAM (Quadrature Amplitude Modulation) in addition to carrier aggregation.
CMTL NTRS GTT MU NTRSP JNPR VZ VZA
Shares of Cisco (CSCO - Free Report) declined 4% to close at $41.78, on Jul 13, following rumors that Amazon Web Services (“AWS”) intends to market network switches to business customers. However, we believe the fears are overblown considering Cisco’s dominant market share, domain expertise and expanding clientele. Per a report, Amazon’s aggressive pricing strategy will not only position it well to foray into the market but also aid it in gaining competitive edge over the companies in the space, including Cisco, Arista Networks (ANET - Free Report) , Juniper (JNPR - Free Report) , among others.
ANET NTRS GTT NTRSP 0722 HPE
Laboratory Corporation of America Holdings (LH - Free Report) also known as LabCorp, is slated to report second-quarter 2018 results on Jul 25 before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 5.30% with its average trailing four-quarter beat being 3.85%.
ALGN BSX NTRS GTT NTRSP BAX
Thermo Fisher Scientific Inc. (TMO - Free Report) is slated to report second-quarter 2018 results before the market opens on Jul 25. Last reported quarter, the company delivered a positive earnings surprise of 3.31%. Moreover, Thermo Fisher surpassed estimates in all the trailing four quarters with an average beat of 3.16%.
ALGN BSX NTRS GTT TMO NTRSP BAX
Johnson & Johnson (JNJ - Free Report) announced that the FDA has extended the review timeline for a supplemental new drug application (sNDA) with respect to its SGLT2 inhibitor, Invokana. The sNDA seeks the regulatory body’s approval for a new indication of risk reduction of cardiovascular events in type II diabetes patients at a risk of cardiovascular (CV) disease.
NTRS GTT JNJ NTRSP VNDA GHDX
Netflix’s (NFLX - Free Report) content portfolio is firing on all cylinders, which is evident from the massive number of Emmy nominations it received this year, topping HBO. Netflix’s plan of creating a huge number of original shows has helped the company dominate streaming market despite stiff competition from Amazon (AMZN - Free Report) Prime, Hulu, Facebook (FB - Free Report) Watch and Apple (AAPL - Free Report) Music.
FB DB NTRS GTT NTRSP AAPL NFLX
Estimates for Murphy Oil Corporation (MUR - Free Report) have been revised upward over the past 60 days, raising analysts’ optimism on the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings per share have moved 37.7% and 57.7% north to $1.68 and $1.94, respectively. El Dorado, AR-based Murphy Oil is a global oil and gas exploration and production company. The company explores and produces crude oil, natural gas and natural gas liquids (NGL) worldwide.
COP WLL NTRS GTT NTRSP MUR.WI MUR OXY
Brown & Brown, Inc.’s (BRO - Free Report) unit Brown & Brown of Arkansas, Inc. recently purchased all the assets of Coffman-Standridge Incorporated d/b/a CSI Insurance. Apart from strengthening capabilities to serve clients better, the buyout will help consolidate the acquirer’s foothold in Central Arkansas. The financial details of the acquisition have been kept undisclosed. Established in 2010, CSI Insurance deals in property and casualty insurance products and services while generating annual revenues of about $1.
AIZ KMPR NTRS GTT KMPA NTRSP BRO
Facebook’s (FB - Free Report) strong belief that technologies like Artificial Intelligence (AI) will revolutionize the future and emerge as big business opportunities is helping the company take proactive steps in this direction. The recent hiring of Shahriar Rabii, Alphabet (GOOGL - Free Report) division Google’s AI head of chip development reflects Facebook’s growing focus in this area Rabii was instrumental in helping the “lead team in charge of building chips for Google’s devices, including the Pixel smartphone’s custom Visual Core chip, which brought machine learning intelligence to the device's camera.
FB NTRS GTT GOOGL NTRSP AAPL
U.S. Bancorp (USB - Free Report) is scheduled to report second-quarter 2018 results on Jul 18, before the opening bell. The bank’s revenues and earnings are anticipated to reflect year-over-year growth. Benefits of higher rates and improved lending scenario are anticipated to have offset the muted trading performance. The Zacks Consensus Estimate for sales of $5.6 billion reflects a rise of 3.7% from the year-ago quarter.
STT STI.WS.B STI.WS.A STT.PRC NTRSP STT.PRE STT.PRD STT.PRG USB STI NTRS GTT STI-A STI.PRE CFR
Earnings Whispers Our proven model cannot conclusively predict if Dover will beat the Zacks Consensus Estimate this time. That’s because it doesn’t have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
NTRS GTT NTRSP DOV
Freeport-McMoRan Inc. (FCX - Free Report) recently announced that it has entered into a non-binding Heads of Agreement with Rio Tinto — PT Freeport Indonesia’s (PT-FI) joint venture (JV) partner — and the Indonesian state-owned enterprise, PT Indonesia Asahan Aluminium (Inalum). Per the deal, Inalum will acquire all of Rio Tinto's interests related to the JV with PT-FI for cash consideration of $3.
RIO BLT RIO NTRSP BHPBF FCX RTPPF BHP NTRS GTT RIO KMG RTNTF BBL BHP BHPLF MEOH
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET